The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling
Open accessAbstract
SUMMARY Pyruvate transport across the inner mitochondrial membrane is believed to be a prerequisite step for gluconeogenesis in hepatocytes, which is important for maintenance of normoglycemia during prolonged food deprivation, but also contributes to hyperglycemia in diabetes. To determine the requirement for mitochondrial pyruvate import in gluconeogenesis, mice with liver-specific deletion of mitochondrial pyruvate carrier 2 (LS-Mpc2−/−) were generated. Loss of MPC2 impaired, but did not completely abolish, hepatocyte pyruvate metabolism, labelled pyruvate conversion to TCA cycle intermediates and glucose, and glucose production from pyruvate. Unbiased metabolomic analyses of livers from fasted LS-Mpc2−/− mice suggested that alterations in amino acid metabolism, including pyruvate-alanine cycling, might compensate for loss of MPC2. Indeed, inhibition of pyruvate-alanine transamination further reduced mitochondrial pyruvate metabolism and glucose production by LS-Mpc2−/− hepatocytes. These data demonstrate an important role for MPC2 in controlling hepatic gluconeogenesis and illuminate a compensatory mechanism for circumventing a block in mitochondrial pyruvate import.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hatori, M., Vollmers, C., Zarrinpar, A., DiTacchio, L., Bushong, E. A., Gill, S., Leblanc, M., Chaix, A., Joens, M., Fitzpatrick, J. A. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.019 · Cited by 1,986
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“Metformin, which acts in the liver to inhibit gluconeogenesis (Foretz et al., 2010), has been used for years to lower blood glucose in type 2 diabetic patients.”
BackgroundA Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and Humans
Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y.-C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., et al. (2012) · Science · doi:10.1126/science.1218099 · Cited by 843
The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors
Halestrap, A. P. (1975) · Biochemical Journal · doi:10.1042/bj1480085 · Cited by 543
Satapati, S., Sunny, N. E., Kucejova, B., Fu, X., He, T. T., Méndez-Lucas, A., Shelton, J. M., Perales, J. C., Browning, J. D., & Burgess, S. C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m023382 · Cited by 407 · cited 2×
“, 2006) and is deranged in the diabetic liver (Satapati et al., 2012).”
BackgroundSelf-citationThiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308 · cited 6×
“Several cinnamate analogs (including UK-5099) (Halestrap, 1975) and thiazolidine ring-containing compounds designed as KATP channel agonists (Hildyard et al., 2005) and insulin-sensitizing thiazolidinediones (troglitazone, rosiglitazone, pioglitazone, MSDC0160, and MSDC-0602) (Divakaruni et al., 2013) inhibit the MPC.”
BackgroundInfluentialSelf-citationRegulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier
Vacanti, N. M., Divakaruni, A. S., Green, C. R., Parker, S. J., Henry, R. R., Ciaraldi, T. P., Murphy, A. N., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.024 · Cited by 277 · cited 2×
“Indeed, recent work in cultured cells has shown that enhanced use of these amino acids as TCA cycle substrates helps to allow cells to survive in the context of MPC deficiency (Du et al., 2013; Vacanti et al., 2014; Yang et al., 2014), and the present in vivo studies are consistent with this.”
ResultColca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061551 · Cited by 171 · cited 7×
“TZD Photoaffinity Crosslinking The iodinated (125I) photoprobe MSDC-1101 was used for photoaffinity crosslinking of crude mitochondrial membranes from isolated fl/fl and LS-Mpc2 / hepatocytes as described previously (Colca et al., 2004, 2013).”
BackgroundMethodInfluentialSelf-citation
Cited by
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“, 2015) or MPC2 (McCommis et al., 2015) did not alter glucose production on a C57BL/6 background where the block in MPC was bypassed with flux into the mitochondria as alanine and mitochondrial alanine transaminase.”
InfluentialEmerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Self-citationThe past and present of serum aminotransferases and the future of liver injury biomarkers
McGill, M. R. (2016) · EXCLI journal · doi:10.17179/excli2016-800 · Cited by 487
Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.05.006 · Cited by 455
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure
Cluntun, A. A., Badolia, R., Lettlova, S., Parnell, K. M., Shankar, T. S., Diakos, N. A., Olson, K. A., Taleb, I., Tatum, S. M., Berg, J. A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.003 · Cited by 345
Mitochondrial Pyruvate Import Promotes Long-Term Survival of Antibody-Secreting Plasma Cells
Lam, W. Y., Becker, A. M., Kennerly, K. M., Wong, R., Curtis, J. D., Llufrio, E. M., McCommis, K. S., Fahrmann, J., Pizzato, H. A., Nunley, R. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.011 · Cited by 283
Self-citationMetabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 282
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Self-citationCappel, D. A., Deja, S., Duarte, J. A. G., Kucejova, B., Iñigo, M., Fletcher, J. A., Fu, X., Berglund, E. D., Liu, T., Elmquist, J. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.014 · Cited by 242
“Likewise, deleting the mitochondrial pyruvate carrier (MPC) resulted in reduced hepatic gluconeogenesis and protection from hyperglycemia during either insulin deficiency (McCommis et al., 2015) or insulin resistance (Gray et al.”
BackgroundSelf-citationIns and outs of the TCA cycle: the central role of anaplerosis
Inigo, M., Deja, S., & Burgess, S. C. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120420-025558 · Cited by 189
The multifaceted pyruvate metabolism: role of the mitochondrial pyruvate carrier
Zangari, J., Petrelli, F., Maillot, B., & Martinou, J.-C. (2020) · Biomolecules · doi:10.3390/biom10071068 · Cited by 172
Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies
Olson, K. A., Schell, J. C., & Rutter, J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.01.002 · Cited by 154
Metabolic Remodeling during Liver Regeneration
Caldez, M. J., Van Hul, N., Koh, H. W. L., Teo, X. Q., Fan, J. J., Tan, P. Y., Dewhurst, M. R., Too, P. G., Talib, S. Z. A., Chiang, B. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.09.020 · Cited by 133
Tompkins, S. C., Sheldon, R. D., Rauckhorst, A. J., Noterman, M. F., Solst, S. R., Buchanan, J. L., Mapuskar, K. A., Pewa, A. D., Gray, L. R., Oonthonpan, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.098 · Cited by 79
The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state
Tavoulari, S., Thangaratnarajah, C., Mavridou, V., Harbour, M. E., Martinou, J., & Kunji, E. R. (2019) · The EMBO Journal · doi:10.15252/embj.2018100785 · Cited by 73
Mitochondrial pyruvate carrier function in health and disease across the lifespan
Buchanan, J., & Taylor, E. (2020) · Biomolecules · doi:10.3390/biom10081162 · Cited by 40
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
Self-citation
Metadata
- Authors
- McCommis, K. S., Chen, Z., Fu, X., McDonald, W. G., Colca, J. R., Kletzien, R. F., Burgess, S. C., & Finck, B. N.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 22
- Issue
- 4
- Pages
- 682-694
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W1932854961
- Cited by
- 213
- References
- 8
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.